Trial of CBD for children and teens with autism spectrum disorder

30 Aug Trial of CBD for children and teens with autism spectrum disorder

Clinicians at Seattle Children’s are trying to learn more about Autism Spectrum Disorder (ASD) and to examine the effects of an investigational medication, called GWP42003-P (a cannabidiol oral solution). We are conducting this study to look at whether or not this medicine helps communication, social skills, and patterns of behavior in children and adolescents with ASD. If your child is aged between 6 and 17 years, and has a diagnosis of ASD and episodes of irritability, please feel free to contact our study coordinator, Stacy Riffle, at 206-987-7502 or email SCACstudies@seattlechildrens.org to find out more.

Participant Eligibility

Age 6-17 with a diagnosis of ASD and IQ of at least 70 (will confirm at screening)
Episodes of irritability or symptoms of ASD causing functional impairment or distress
Ability to swallow liquid medication.

Exclusions include current diagnoses of some mental disorders (for example schizophrenia), recent seizures, certain drugs (such as omeprazole), known or suspected history of alcohol or substance abuse, history of suicidal behavior.

Contact

Stacy Riffle
(206) 987-7502